Rein Therapeutics releases update on Phase 2 RENEW trial enrollment expansion
RNTX•Phase 2 RENEW trial enrolls across five countries
Rein Therapeutics posted a press release stating its Phase 2 RENEW trial of inhaled LTI-03 in idiopathic pulmonary fibrosis is enrolling across five countries.
The randomized, placebo-controlled study targets about 120 patients.
Initial topline data remain slated for 2H 2026.
